TRIB (Trinity Biotech) LT-Debt-to-Total-Asset: 0.26 (As of Dec. 2025)

What is Trinity Biotech LT-Debt-to-Total-Asset?

Trinity Biotech TRIB +17.06% 26 LT-Debt-to-Total-Asset is 0.26 as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 26/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Trinity Biotech's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.26.

Trinity Biotech's long-term debt to total assets ratio declined from Dec. 2024 (0.95) to Dec. 2025 (0.26). It may suggest that Trinity Biotech is progressively becoming less dependent on debt to grow their business.

Trinity Biotech (NAS:TRIB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Trinity Biotech LT-Debt-to-Total-Asset Related Terms

Trinity Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech LT-Debt-to-Total-Asset Chart

Trinity Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.76

1.10

0.95

0.26

Trinity Biotech Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															1.10	0.96	0.95	1.11	0.26

26GF Score

Trinity Biotech PLC TRIB

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Trinity Biotech LT-Debt-to-Total-Asset Calculation

Trinity Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	27.17	/	105.165
	=	0.26

Trinity Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	27.17	/	105.165
	=	0.26

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.26 mean?

Trinity Biotech (TRIB) has a LT-Debt-to-Total-Asset of 0.26 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Trinity Biotech and its competitors.

Is Trinity Biotech's LT-Debt-to-Total-Asset too high?

Trinity Biotech's current LT-Debt-to-Total-Asset is 0.26. Overall, Trinity Biotech has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Trinity Biotech's LT-Debt-to-Total-Asset compare to AIDX and NVNO?

Trinity Biotech's LT-Debt-to-Total-Asset of 0.26 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current LT-Debt-to-Total-Asset is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Trinity Biotech stock overvalued right now?

Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.42 — trading 42.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.26. Trinity Biotech's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current LT-Debt-to-Total-Asset is 0.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.42 is trading 42.8% below its estimated GF Value™ of $0.73. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

LT-Debt-to-Total-Asset: 0.26
GF Value™: $0.73 vs. price of $0.42 (42.8% below fair value)
GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies AIDX NVNO STME NXL VVOS XAIR TNON CSDX BMRA INBS ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.

26GF Score

Get the complete analysis for TRIB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42

Price

$0.73

GF Value

View TRIB Analysis

See LT-Debt-to-Total-Asset data for all stocks →